The ARTBIO Approach: Patients at the Core

Radioligand therapy (RLT) has offered a promising new approach for cancer treatment. While beta radioligand therapies are currently more common in clinical practice, alpha radioligand therapies offer potentially significantly better efficacy and safety to patients.

The ARTBIO approach is holistic. It is underpinned by a deep understanding of cancer biology, and the infrastructure needed to effectively design, manufacture, and distribute our therapies.

Our patient-centric approach rests on four pillars:

About bg

A Differentiated Pipeline

We are identifying specific combinations of targets and drug molecules best suited for ART. Our ARTs have high affinity and selectivity in order to effectively kill tumors while sparing healthy tissues.

Currently, ARTBIO has four pipeline programs with many more in development:
  • Our lead program AB001 has entered first in human studies.
  • Three additional targets (ABA, ABB, and ABC) remain undisclosed.

Programs
Indication
Discovery
Lead Optimization
Phase 0
Clinical Stage (Phase 1-3)
AB001
212Pb-NG001
Prostate Cancer
Phase 0
ABA
212Pb-undisclosed
Multiple Solid Tumors
Lead Optimization
ABB
212Pb-undisclosed
Multiple Solid Tumors
Lead Optimization
ABC
212Pb-undisclosed
Multiple Solid Tumors
Discovery

A Team of Pioneers and Innovators in RLT

ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy. Born out of groundbreaking research conducted at the University of Oslo and Norway’s Radium Hospital - a research hub with lineage to Marie Curie - ARTBIO’s roots in radiology and radiation therapy run deep. Our scientific founders, Roy Larsen and Øyvind Bruland, invented Xofigo (later acquired by Bayer via Algeta), the first-ever metabolically targeted alpha therapy. Both collaborated with the F-Prime team and Radforsk to lay the foundation of ARTBIO in 2021.

Our team is composed of multi-disciplinary experts with decades of experience in advancing complex drugs through all stages of clinical development. We are driven by the power of collective thinking, diversity, and a passion to create smarter solutions together. Finally, we take pride in combining creativity and scientific expertise to address challenges. We value inclusion, collaboration, and fostering strong relationships with our team, partners, health care.

  • Management Team
  • Scientific Founders
  • Scientific Advisory Board
  • Board of Directors
Arrow
Emanuele Ostuni, PhD

Emanuele Ostuni, PhD

Founding CEO

Nick Pullen, PhD

Nick Pullen, PhD

Chief Scientific Officer

Philippe Dasse, PharmD

Philippe Dasse, PharmD

Chief Technical Officer

Conrad Wüller, MSc

Conrad Wüller, MSc

Senior Director, Strategy and Operations

Calvin Lee, MBA

Calvin Lee, MBA

Vice President, Finance

Vicki Jardine, MD, PhD

Vicki Jardine, MD, PhD

Vice President, Clinical Development

Lily Bouzelmat, MSc

Lily Bouzelmat, MSc

Vice President, Development Operations

Jordi Vall-llosera Ferran

Jordi Vall-llosera Ferran

Senior Vice President and Global Head of Quality

Victor Paulus, PhD

Victor Paulus, PhD

Head and Senior Vice President, Regulatory Affairs

Daniel Rossetto, MSc

Daniel Rossetto, MSc

Head & SVP, Supply Chain and External Manufacturing

Tanja Aarvak, PhD

Tanja Aarvak, PhD

Director, Drug Product Development and Manufacturing

Gjermund Fjeld Olsen, MSc

Gjermund Fjeld Olsen, MSc

Director, Generator Development and Manufacturing

Bharat Lagu, PhD

Bharat Lagu, PhD

Senior Vice President, Discovery

Ada Repetto-Llamares, PhD

Ada Repetto-Llamares, PhD

Director, Translational Biology

Phil Ruis, PhD

Phil Ruis, PhD

Director, Partnered Discovery and Business Development

Roy H. Larsen, Ph.D.

Roy H. Larsen, Ph.D.

Scientific Co-⁠Founder

Øyvind Bruland, MD, PhD

Øyvind Bruland, MD, PhD

Scientific Co-⁠Founder

 Øyvind Bruland, MD, PhD

Øyvind Bruland, MD, PhD

SAB Chairman and ARTBIO Co-⁠Founder

Roy H. Larsen, PhD

Roy H. Larsen, PhD

ARTBIO Co-⁠founder

Oliver Sartor, MD

Oliver Sartor, MD

Advisor

Richard P. Baum, MD, PhD

Richard P. Baum, MD, PhD

Advisor

Dennis Benjamin, MD

Dennis Benjamin, MD

Advisor

Ted W. Love, MD

Ted W. Love, MD

Chairman

Roy H. Larsen, PhD

Roy H. Larsen, PhD

ARTBIO Co-founder, Sciencons

Jeffrey Tong, PhD

Jeffrey Tong, PhD

Partner, Third Rock Ventures

Ranjeev (Ronny) Krishana

Ranjeev (Ronny) Krishana

Susanne Schaffert, PhD

Susanne Schaffert, PhD

Independent

Alex Pasteur, PhD

Alex Pasteur, PhD

Partner, F-Prime Capital

Otello Stampacchia, Ph.D.

Otello Stampacchia, Ph.D.

Managing Director and Founder, Omega Funds

Emanuele Ostuni, PhD

Emanuele Ostuni, PhD

Founding CEO, ARTBIO

Anders Tuv

Anders Tuv

Partner, Radforsk (Observer)

Martin Taylor, PhD

Martin Taylor, PhD

Senior Associate, F-Prime (Observer)

Francesco Draetta

Francesco Draetta

Partner, Omega Funds (Observer)

Investors

News background shapeNews background shape

News

Learn about the latest ARTBIO news.
Arrow
Arrow

Join our team

The journey is better together.

Together, we approach challenges head-on and with an open mind. Join our team to help us usher in an entirely new standard of care for cancer patients.

Join us if you are...

bg-sky-blue shapepassionate about making a difference for cancer patients
bg-orange shapea humble achiever
bg-pink shapea practical optimist
bg-yellow shapea consummate learner and un-learner
bg-voilet shapedriven by data and cherish transparency
bg-orange shapea compassionate team player

Open positions

There are currently no open positions available, please check back soon.